Abstract
BackgroundHigh expression of proviral integration site for Moloney murine leukemia virus-1 (PIM-1), a serine/threonine kinase, is associated with many cancers. The main purpose of this study were to investigate that the correlation between PIM-1 mRNA levels and clinicopathologic features and its clinical significance in acute myeloid leukemia (AML).MethodsqRT-PCR was performed for 118 de novo AML and 20 AML complete remission patients and 15 normal individuals. All statistical analysis were performed using Graphpad Prism5 software.ResultsWe observed that expression of PIM-1 mRNA was higher in AML patients than in healthy individuals and in complete remission AML patients (P = 0.0177). Further, high PIM-1 mRNA levels were more associated with high-risk FLT3+ AML patients than the FLT3− group (P = 0.0001) and were also associated with clinical factors such as risk stratification (P = 0.0029) and vital status (P = 0.0322). Kaplan–Meier survival analysis indicated that PIM-1 mRNA expression correlated with overall survival (OS), disease free survival (DFS), and relapse rate (RR) in AML patients. Most importantly, the high PIM-1-expressing patients took longer to achieve complete remission than the low expression group (P = 0.001). In addition, the complete remission rate was significantly lower in the high PIM-1 group (P = 0.0277) after induction therapy.ConclusionsAbove results suggest that PIM-1 mRNA levels may be an independent prognostic factor in AML.
Highlights
High expression of proviral integration site for Moloney murine leukemia virus-1 (PIM-1), a serine/ threonine kinase, is associated with many cancers
We found that the expression of PIM-1 was associated with poor prognosis of acute myeloid leukemia (AML) patients
Clinical characteristics of patients with AML In present study, we evaluated 118 de novo AML patients, 35 AML complete remission patients and normal individuals as controls
Summary
High expression of proviral integration site for Moloney murine leukemia virus-1 (PIM-1), a serine/ threonine kinase, is associated with many cancers. The PIM-1 gene is a proto-oncogene located on chromosome 6p21 that encodes a serine/threonine kinase, found mostly in hematopoietic cells as a member of the PIM family [1]. It was originally identified as a proviral integration site for Moloney murine leukemia virus-1 [2]. There is rapid improvement in risk stratification of AML gene mutations and development of many new drugs such as monoclonal anti-CD33 antibody, inhibitor of mutant IDH1 and IDH2 and inhibitor of DOT1L, majority of patients still experience relapse and succumb to the disease [17–20]. Little data is known regarding the impact of PIM-1 mRNA overexpression on prognosis in AML patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
